-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Beijing, September 16, 2021/PRNewswire/ - Nuocheng Jianhua (Hong Kong Stock Exchange code: 09969) and Connoa (Hong Kong Stock Exchange code: 02162) jointly announced today that they have received the National Drug Administration The “Notice of Drug Clinical Trial Approval” approved and issued by the Bureau agreed to the CD20xCD3 bispecific antibody CM355 developed by the joint venture company Tennuo Jiancheng to carry out clinical trials of CD20+ B-cell hematoma
CM355 specifically binds to CD20 positive target cells and CD3 positive T cells, recruits immune T cells around the target cells, activates T cells, induces T cell-mediated tumor cell killing (TDCC) to kill target cells, and is used to treat CD20+ B cell hematoma
Non-Hodgkin’s lymphoma (NHL) is the main type of CD20+ B-cell hematoma, accounting for 80%-90% of B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma ( FL), mantle cell lymphoma (MCL), chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL) and the like
Dr.
Dr.
On September 3, 2021, Nuocheng Jianhua and Connoa signed a strategic cooperation agreement at the 2021 China International Trade in Services Fair to further deepen the R&D cooperation between the two parties and devote themselves to the development of First-in-class and Best-in-class macromolecules Innovative drugs benefit patients
About Nuocheng Jianhua
Nuocheng Jianhua (Hong Kong Stock Exchange code: 09969) is a commercialized biomedical high-tech company, focusing on the development of a class of new drugs in the treatment of malignant tumors and autoimmune diseases, suitable for the treatment of lymphoma and solid tumors And autoimmune diseases
About Connoa
Connoa (Hong Kong Stock Exchange code: 02162) was founded by a number of experts who graduated from world-renowned universities and have rich experience in the transformation of scientific and technological achievements and domestic and foreign industrialization.
Connoa focuses on the research and development and industrialization of innovative antibody drugs, and builds a diversified and differentiated product pipeline for autoimmune and tumor fields
Nuocheng Jianhua forward-looking statement
This press release contains the disclosure of certain forward-looking statements
